When was Genomind founded?

Genomind was founded in 2009 and raised its 1st funding round 5 years after it was founded.

Where is Genomind located?

Genomind is headquartered in King Of Prussia, United States. It is registered at 2200 Renaissance Blvd Suite 100, King Of Prussia, PA 19406, US.

How many employees does Genomind have?

As of Jun 30, 2026, the latest employee count at Genomind is 54.

Is Genomind a funded company?

Genomind is a funded company, having raised a total of $64.4M across 8 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 09, 2014.

When was the latest funding round of Genomind?

Genomind's latest funding was a $***** Grant (prize money) round on Feb 10, 2025, with participation from 1 investor. Its primary sector is Neurology. In United States, the Neurology sector has seen $4.63B in funding in 2026 to date.

Where does Genomind rank among its competitors?

Genomind ranks 15th amongst 181 active competitors, of which 46 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Solid Biosciences, which secured $240M in Mar, 2026.

Who are the top competitors of Genomind?

Genomind's top competitors include Helix, Caris Life Sciences and UniQure. Among them, Solid Biosciences secured the most recent funding round in March, 2026.

Genomind - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of genetic tests for personalised medicines to enhance mental health treatment. It offers Genomind's PGx test that examines genes related to mental health treatment, providing insights into how a patient may metabolize or respond to different medication. It also offer Mental Health Map a DNA test that assesses genetic predispositions across core mental health capabilities, including mood, focus, and stress responses.

Website: genomind.com
Social
Email ID: *****@genomind.com
Phone Number: +1 **********
Registered Address: 2200 Renaissance Blvd Suite 100, King Of Prussia, PA 19406, US

Key Metrics

Founded Year

2009

Location

King Of Prussia, United States

Stage

Series C

Total Funding

$64.4M in 8 rounds

Latest Funding Round

Grant (prize money), Feb 10, 2025, $*****

Investors

Claritas Capital & 2 more

Ranked

15^th among 181 active competitors

Employee Count

54 as on Jun 30, 2026

Similar Companies

MyHeritage & 532 more

View Genomind's full profile

Genomind is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Genomind, Inc. CIN: 20141282403 , United States, Active	May 01, 2014	-	-	-

Genomind has raised a total funding of $64.4M over 8 rounds. Its first funding round was on Apr 09, 2014. Its latest funding round was a Grant (prize money) round on Feb 10, 2025 for $*****. 1 investor participated in its latest round. Genomind has 3 institutional investors.

Here is the list of recent funding rounds of Genomind:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 10, 2025	1156838	Grant (prize money)	8193093	8963295	9767157	8079318
Sep 21, 2023	5971720	Grant (prize money)	9809817	2954860	1150906	HHS
Apr 22, 2021	2590344	Series C	9552067	8332874	2855128	2440302

Access funding benchmarks and valuations. Sign up today!

View details of Genomind's funding rounds and investors

Genomind's Board of Directors

Genomind's board has 19 active members. Beth Dozoretz, John Chadwick, Thomas Hess, Theresa Sexton, Joseph Anton, Beth E. Dozoretz, Brad Lucas, Shelloy Kiger, Michael Koffler, Tom Hess, Stacy Williams, Shawn Patrick O'Brien, Gloria Nuss, Shawn P. O'Brien, Kip Olmstead, Stephen Haller, Ronald I. Dozoretz, Scott Storrer and Rina Wolf are independent board members.

Here is the list of Genomind's board of directors:

Name	Type	Representing	Status	Duration
Beth Dozoretz	Independent board member	-	Current	5y 5m
ikvrpnu	Independent board member	-	Current	7y 9m
urgdpu{	Independent board member	-	Current	5y 7m
mconely	Independent board member	-	Current	8y 7m
tynqvkh	Independent board member	-	Current	5y 9m
hkqdj{b	Independent board member	-	Current	1y 3m
dtsdcji	Independent board member	-	Current	7y 5m
wohuoug	Independent board member	-	Current	7y 1m
hhirpwt	Independent board member	-	Current	7y 9m
mf{vply	Independent board member	-	Current	7y 9m
vwblkdc	Independent board member	-	Current	1y 1m
jfeywqo	Independent board member	-	Current	5y 2m
upr{etj	Independent board member	-	Current	3y 7m
cfsufxt	Independent board member	-	Current	8y 5m
qsggvsj	Independent board member	-	Current	5y 5m
{gcrtob	Independent board member	-	Current	1y 6m
mhxyfid	Independent board member	-	Current	4y 6m
cvaqnn{	Independent board member	-	Current	6y 3m
srogihm	Independent board member	-	Current	3y 4m

Genomind's employee count trend

Genomind has 54 employees as of Jun 26. Here is Genomind's employee count trend over the years:

Uncover Genomind's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Genomind include Helix, Caris Life Sciences and UniQure. Here is the list of Top 10 competitors of Genomind, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Helix 2015, San Francisco (United States), Series E	Provider of a genomic database for clinical research	$435M	DFJ Growth, Kleiner Perkins & 12 others	71/100
2nd	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Coatue & 19 others	71/100
3rd	UniQure 1998, Amsterdam (Netherlands), Public	Developer of gene-based therapies for patients with genetic or acquired diseases	$111M	Gilde Healthcare, Advent Life Sciences & 11 others	62/100
4th	Regulus Therapeutics 2007, San Diego (United States), Acquired	Innovative medicines company reimagining medicine to improve and extend people’s lives	$35M	Ionis Pharmaceuticals, Alnylam & 8 others	62/100
5th	Repare Therapeutics 2016, Montreal (Canada), Acquired	Developer of targeted therapies to address the genetic alterations associated with selected tumors	$166M	Versant Ventures, Cowen & 13 others	60/100
6th	Seres Therapeutics 2010, Cambridge (United States), Public	Developer of microbiome therapeutics to treat a wide range of diseases	$134M	Flagship Pioneering, Mayo Clinic Business Accelerator ... & 8 others	60/100
7th	Exicure 2009, Skokie (United States), Public	developer of gene silencing & immunomodulatory drugs using spherical nucleic acid (SNA) technology	$72.3M	Abbott Biotech Ventures, Luye Pharma & 18 others	60/100
8th	Exosome Diagnostics 2008, Boston (United States), Acquired	Developer of blood-based cancer molecular diagnostics for patient stratification and disease monitoring	$119M	Forbion, NGN Capital & 7 others	60/100
9th	Solid Biosciences 2014, Cambridge (United States), Public	Developer of gene therapy platform for Duchenne muscular dystrophy	$92.5M	Bain Capital Life Sciences, RA Capital Management ... & 18 others	60/100
10th	Helomics 1995, Pittsburgh (United States), Acquired	AI-driven platform to develop precisely targeted therapies for cancer patients	$196M	Bain Capital Ventures, Quaker Partners & 9 others	60/100
15th	Genomind 2009, King Of Prussia (United States), Series C	Developer of genetic tests for personalised medicines to enhance mental health treatment	$64.4M	SVB, Claritas Capital & 1 others	56/100